Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 14, 2009 - Issue 1
Submit an article Journal homepage
72
Views
6
CrossRef citations to date
0
Altmetric
Review

Emerging drugs for the treatment of tobacco dependence

Jon O Ebbert Associate Professor of Medicine Mayo Clinic College of Medicine, 200 First Street Southwest, MN 55905, Rochester, USA +1 507 266 1944; +1 507 266 7900; [email protected]
, MD MSc
Pages 23-32 | Published online: 28 Jan 2009

Bibliography

  • World Health Organization. The facts about smoking and health, 2006. Available from: http://www.wpro.who.int/media_centre/fact_sheets/fs_20060530.htm
  • World Health Organization. Smoking Statistics, 2002. Available from: http://www.wpro.who.int/media_centre/fact_sheets/fs_20020528.htm
  • US Department of Health and Human Services. The health consequences of smoking: Nicotine addiction. A report of the Surgeon General (Publication No. 88-8406). Washington, DC: US Government Printing Office; 1988
  • Stolerman IP, Jarvis MJ. The scientific case that nicotine is addictive. Psychopharmacology (Berl) 1995;117(1):2-10; discussion 4-20
  • Koob GF. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 1992;13(5):177-84
  • Pontieri FE, Tanda G, Orzi F, et al. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996;382(6588):255-7
  • Dani JA, Heinemann S. Molecular and cellular aspects of nicotine abuse. Neuron 1996;16(5):905-8
  • Corringer PJ, Le Novere N, Changeux JP. Nicotinic receptors at the amino acid level. Annu Rev Pharmacol Toxicol 2000;40:431-58
  • Picciotto MR, Zoli M, Rimondini R, et al. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 1998;391(6663):173-7
  • Marubio LM, Gardier AM, Durier S, et al. Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors. Eur J Neurosci 2003;17(7):1329-37
  • American Cancer Society. Cancer Facts and Figures 2007. Available from: www.cancer.org
  • Annual smoking-attributable mortality, years of potential life lost, and economic costs: United States, 1995-1999. MMWR Morb Mortal Wkly Rep 2002;51(14):300-3
  • Center for Disease Control. Annual smoking-attributable mortality, years of potential life lost, and productivity losses: United States, 1997-2001. Morb Mortal Wkly Rep 2005;54(25):625-8
  • US Department of Health and Human Services. The health benefits of smoking cessation: a report of the Surgeon General, 1990. Publication No. (CDC) 90-8416. Washington, DC: US Department of Health and Human Services, Public Health Service, Centers for Disease Control, Office on Smoking and Health; 1990
  • Centers for Disease Control and Prevention. Cigarette smoking among adults: United States, 2006. MMWR Morb Mortal Wkly Rep 2007;56(44):1157-61
  • Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults – United States, 2000. MMWR Morb Mortal Wkly Rep 2002;51(29):642-5
  • Fu SS, Partin MR, Snyder A, et al. Promoting repeat tobacco dependence treatment: are relapsed smokers interested? Am J Manag Care 2006;12(4):235-43
  • Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Rockville, MD: US Department of Health and Human Services, Public Health Service; 2008
  • Ferris RM, Cooper BR. Mechanism of antidepressant activity of bupropion. J Clin Psychiatry 1993;11(1):2-14
  • Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000;295(1):321-7
  • Damaj MI, Carroll FI, Eaton JB, et al. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol 2004;66(3):675-82
  • McCarthy DE, Piasecki TM, Lawrence DL, et al. Psychological mediators of bupropion sustained-release treatment for smoking cessation. Addiction 2008;103(9):1521-33
  • Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997;337(17):1195-202
  • Jorenby DE, Leischow SJ, Nides M, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340(9):685-91
  • Burke MV, Ebbert JO, Hays JT. Treatment of tobacco dependence. Mayo Clin Proc 2008;83(4):479-83; quiz 83-4
  • Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007;1:CD000031
  • Ferguson SG, Shiffman S, Gwaltney CJ. Does reducing withdrawal severity mediate nicotine patch efficacy? A randomized clinical trial. J Consult Clin Psychol 2006;74(6):1153-61
  • Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008;1:CD000146
  • Hughes JR, Shiffman S, Callas P, et al. A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control 2003;12(1):21-7
  • West R, Hajek P, Nilsson F, et al. Individual differences in preferences for and responses to four nicotine replacement products. Psychopharmacology (Berl) 2001;153(2):225-30
  • Tonnesen P, Norregaard J, Mikkelsen K, et al. A double-blind trial of a nicotine inhaler for smoking cessation. JAMA. 1993;269(10):1268-1271
  • Blondal T, Franzon M, Westin A. A double-blind randomized trial of nicotine nasal spray as an aid in smoking cessation. Eur Respir J 1997;10(7):1585-90
  • Hurt RD, Dale LC, Croghan GA, et al. Nicotine nasal spray for smoking cessation: pattern of use, side effects, relief of withdrawal symptoms, and cotinine levels. Mayo Clin Proc 1998;73(2):118-25
  • Choi JH, Dresler CM, Norton MR, et al. Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res 2003;5(5):635-44
  • Shiffman S, Dresler CM, Hajek P, et al. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med 2002;162(11):1267-76
  • Ebbert JO, Sood A, Hays JT, et al. Treating tobacco dependence: review of the best and latest treatment options. J Thorac Oncol 2007;2(3):249-56
  • Smith JW, Mogg A, Tafi E, et al. Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat. Psychopharmacology (Berl) 2007;190(2):157-70
  • Tutka P. Nicotinic receptor partial agonists as novel compounds for the treatment of smoking cessation. Expert Opin Investig Drugs 2008;17(10):1473-85
  • Reavill C, Walther B, Stolerman IP, et al. Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline. Neuropharmacology 1990;29(7):619-24
  • Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005;48(10):3474-7
  • Lesage MG, Shelley D, Ross JT, et al. Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats. Pharmacol Biochem Behav 2008 Sep 9. [Epub ahead of print]
  • Rollema H, Chambers LK, Coe JW, et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007;52(3):985-94
  • Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006;296(1):64-71
  • Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296(1):47-55
  • Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296(1):56-63
  • Williams KE, Reeves KR, Billing CB Jr, et al. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin 2007;23(4):793-801
  • Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006;166(15):1571-7
  • Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006;166(15):1561-8
  • Tsai ST, Cho HJ, Cheng HS, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007;29(6):1027-39
  • Nakamura M, Oshima A, Fujimoto Y, et al. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007;29(6):1040-56
  • Stapleton JA, Watson L, Spirling LI, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2008;103(1):146-54
  • Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008;63(8):717-24
  • US Food and Drug Administration. Public Health Advisory: Important Information on Chantix (varenicline), 2008. Available from: http://www.fda.gov/CDER/Drug/advisory/varenicline.htm
  • Datamonitor. Nicotine dependence: market potential, 2008. Report No. DMHC2348. www.datamonitor.com
  • Niconovum. 2008. Available from: http://www.niconovum.se/
  • The Institute for Safe Medication Practices. Strong safety signal seen for new varenicline risks, 2008. Available from: http://www.ismp.org/docs/vareniclinestudy.asp
  • Hays JT. The risk-benefit balance of varenicline for smoking cessation. J Thorac Oncol 2008;3(9):949-50
  • Hughes JR. Smoking and suicide: a brief overview. [Letter] Drug Alcohol Depend 2008
  • Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry 2007;164(8):1269
  • Steensland P, Simms JA, Holgate J, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci USA 2007;104(30):12518-23
  • Cornuz J, Zwahlen S, Jungi WF, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One 2008;3(6):e2547

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.